Trinity Biotech ( ($TRIB) ) has shared an update. On February 6, 2025, Trinity Biotech announced significant improvements in its continuous ...

DUBLIN - Trinity Biotech plc (NASDAQ:TRIB), a leader in diabetes management solutions currently trading at $0.86 per share, has announced significant enhancements in the performance of its continuous ...

The latest analysis confirms that first-day accuracy - a critical performance metric for CGM users - shows an approximately 35% improvement in Mean Absolute Relative Difference (MARD) and a more than ...

Trinity Biotech (TRIB) announced new findings from its latest pre-pivotal trial, highlighting significant improvements in first-day performance ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

Using a handheld dynamometer to assess hip flexion and abduction strength during dialysis was reliable and safe, researchers ...

The trial showcased significant enhancements in sensor performance, including superior signal quality, enhanced reliability post-insertion, and breakthrough accuracy with a 25-30% improvement in mean ...

indicating a 25%–30% improvement in the mean absolute relative difference (MARD), a key accuracy measure. Trial participants, many of whom were diagnosed with Type 1 diabetes, wore multiple ...

A 25-30% improvement in the key accuracy metric—mean absolute relative difference (MARD)—over earlier Waveform CGM sensors. Industry-Standard Low-Glucose Precision : Accuracy for low blood ...